Please provide your email address to receive an email when new articles are posted on . Ardelyx Inc. has received FDA approval for its phosphate drug Xphozah. The company said it is the first and only ...
4d
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
INDICATION XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response ...
X-linked hypophosphataemia (XLH) is the most prevalent heritable form of rickets in children and of osteomalacia in adults.
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global ...
Phosphate-binder therapy is associated with reduced mortality in men with non-dialysis-dependent CKD, a study found. The study, led by Csaba P. Kovesdy, MD, of Salem VA Medical Center in Salem, Va., ...
Serum levels of phosphate and parathyroid hormone are lower early in the day and higher late in the day, recently reported data suggest. Phosphate and parathyroid hormone (PTH) levels at the start of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results